MedTrace Logo

Comparative Bioavailability Study of Synerx and Verelan PM 300 mg Verapamil HCl ER Capsules Under Fed Conditions

NCT01467687 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 58

Last updated 2011-11-09

No results posted yet for this study

Summary

The purpose of this study is to determine the bioequivalency of Synerx Pharma Verapamil extended release capsules.

Conditions

  • Healthy

Interventions

DRUG

verapamil controlled release

verapamil 300 mg controlled release capsule as a single dose

Sponsors & Collaborators

  • Synerx Pharma, LLC

    lead INDUSTRY

Principal Investigators

  • Gaetano Morelli, MD · MDS Pharma

Study Design

Allocation
RANDOMIZED
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2007-07-31
Primary Completion
2007-08-31
Completion
2007-08-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01467687 on ClinicalTrials.gov